Advancements in Nanomedicine for Allergic Diseases: Diagnosis, Toxicity, and Therapeutic Strategies
Chemical Research in Toxicology · 17.11.2025 · 38 (11) · 1818-1843
DOI: 10.1021/acs.chemrestox.5c00259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Chemical Research in Toxicology, online erschienen am 27.10.2025. Verfasst von Marzieh Ramezani Farani und 8 weiteren Autor:innen. Beteiligte Einrichtung: NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Incheon 22212, Repub…. Hauptthemen laut MEDLINE: Nanomedicine, Hypersensitivity, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 354 Literaturangaben. Gefördert von: Ministry of Education, National Research Foundation of Korea.
Abstract (Originalsprache)
Allergic diseases affect over one billion people worldwide as a common chronic condition. Conventional treatments often relieve symptoms but lack long-term efficacy or safety. Over the past decade, nanomedicine, i.e., nanoscale drugs and delivery systems, has emerged as a promising alternative that leverages the tunable physicochemical properties of nanoparticles (NPs) and enhances both diagnosis and treatment of hypersensitivity disorders. In diagnostics, nanoparticle-based biosensors have achieved detection limits as low as 42 fg/mL with specificity exceeding 90% for food and aeroallergen proteins. Therapeutic applications comprise various NPs, including gold, silver, iron oxide, carbon-based, lipid-mediated, polymeric, dendrimeric, and virus-like, as delivery vehicles and as immunomodulators. Preclinical models detect >50% reductions in pro-inflammatory cytokines (IL-4, IL-5) and two- to 3-fold reductions in eosinophil infiltration following NP-augmented allergen immunotherapy, with antigen-specific IgE titers reduced by up to 70%. Although such advancement has occurred, nanotoxicology studies highlight dose-dependent organ concentration and prolonged pulmonary half-lives that necessitate rigorous biosafety evaluation. Regulatory and manufacturability concerns remain significant hurdles for clinical translation. This article reviews up-to-date quantitative performance metrics for nanoparticle therapeutics and diagnostics in allergy control, critically examines the toxicity profiles and translational issues, and brings out directions toward individualized, safe nanotheranostic platforms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- NanoBio High-Tech Materials Research Center, Department of Biological Sciences and Bioengineering, Inha University, 100 Inha-ro, Incheon 22212, Republic of Korea.
- Department of Biology, Faculty of Science, University of Tehran, Tehran 14155-6455, Iran.
- Department of Chemistry, Institute for Advanced Studies in Basic Sciences (IASBS), Zanjan 45137-66731, Iran.
- Medical Toxicology and Drug Abuse Research Center, Birjand University of Medical Sciences, Birjand 9717853577, Iran.
- Department of Radiology, Charité─Universitätsmedizin Berlin, Berlin 10117, Germany.
- Centre for Immunology and Infection Control, Faculty of Health, School of Biomedical Sciences, Queensland University of Technology, Brisbane, Queensland 4001, Australia.
ORCID-Profile: Marzieh Ramezani Farani, Abdolreza Simchi, Yun Suk Huh
Förderung
- Ministry of Education
- National Research Foundation of Korea
Zitieren
APA
Ramezani Farani, M., Mirzaee, D., Hassanpour, M., Nayebizadeh, B., Mohades, F., Azarian, M., Chamani, S., Simchi, A., & Huh, Y. S. (2025). Advancements in Nanomedicine for Allergic Diseases: Diagnosis, Toxicity, and Therapeutic Strategies. Chemical Research in Toxicology, 38(11), 1818-1843. https://doi.org/10.1021/acs.chemrestox.5c00259
Vancouver
Ramezani Farani M, Mirzaee D, Hassanpour M, Nayebizadeh B, Mohades F, Azarian M, et al. Advancements in Nanomedicine for Allergic Diseases: Diagnosis, Toxicity, and Therapeutic Strategies. Chemical Research in Toxicology. 2025;38(11):1818-1843. doi:10.1021/acs.chemrestox.5c00259
BibTeX
@article{RamezaniFarani2025,
author = {Ramezani Farani, Marzieh and Mirzaee, Danial and Hassanpour, Mahnaz and Nayebizadeh, Bahareh and Mohades, Fatemeh and Azarian, Maryam and Chamani, Sajjad and Simchi, Abdolreza and Huh, Yun Suk},
title = {Advancements in Nanomedicine for Allergic Diseases: Diagnosis, Toxicity, and Therapeutic Strategies},
journal = {Chemical Research in Toxicology},
year = {2025},
volume = {38},
number = {11},
pages = {1818--1843},
doi = {10.1021/acs.chemrestox.5c00259}
}
EUVIMED